The cell and gene therapy (CGT) contract manufacturing landscape has a new market entrant, and it’s a big one. On May 7, 2026, San Francisco-based private investment firm GI Partners announced that it has completed its acquisition of the Contract Development and Manufacturing Organization (CDMO) and Cell Solutions businesses from Charles River Laboratories International. The combined operations now form Rose BioSolutions (“Rose Bio” for those in the know), a company providing exclusively advanced therapy development and manufacturing. [Read more…]
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel
EMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract development and manufacturing organization (CDMO), today announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel (mivocabtagene autoleucel), Kyverna’s autologous CD19-directed CAR T-cell therapy. [Read more…]
Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges
Backed by a €12M Bpifrance grant, the program builds a GMP-compatible manufacturing platform for iPSC-derived cell therapies — directly applicable to biotech and pharma iPSC programs.
Toulouse, 2026 April 16th – Scale-up remains one of the most critical unsolved challenges in iPSC-derived cell therapy. Despite strong clinical promise, most manufacturing processes today can only supply material for a very limited number of patients — a bottleneck that limits clinical progression and commercial viability across the field. [Read more…]
CHU Toulouse and Cell-Easy Launch A-MUSE, a Phase 1/2 Clinical Trial Evaluating the CellReady® Allogeneic MSC Platform in Systemic Sclerosis
Toulouse, January 22, 2026 — Cell-Easy, a CDMO specialized in the development and GMP manufacturing of Advanced Therapy Medicinal Products (ATMPs), announces a new clinical milestone achieved in close collaboration with Toulouse University Hospital (CHU Toulouse). The European Medicines Agency (EMA) has granted Clinical Trial Authorization (CTA) for AMUSE, a Phase 1/2 clinical trial evaluating the safety and efficacy of an allogeneic mesenchymal stromal cell (MSC) therapy in patients with systemic sclerosis presenting perioral fibrosis and functional impairment. [Read more…]
Cellistic Launches Three New iPSC-based GMP Manufacturing Platforms to advance Immuno-Oncology and Regenerative Cell Therapies
Belgium, Mont Saint-Guibert, 13 January 2026 – Cellistic, a global leader in allogeneic iPSC-derived cell therapy manufacturing, today announced the launch of three new iPSC-derived GMP cell therapy manufacturing platforms: Echo™-T, Echo™-Cardio, and Echo™-Endothelial. The new platforms are designed to advance cell therapies and drive progress across immuno-oncology and regenerative medicine.Building on the success of the Cellistic Echo™-NK manufacturing platform for natural killer (NK) cells, the expanded Cellistic Echo™ portfolio leverages the company’s GMP manufacturing expertise and its EMA-certified, FDA- and PMDA-compliant manufacturing facility. Through dedicated platform development, these capabilities are extended to deliver scalable solutions across additional immune and regenerative cell types.
[Read more…]